Dose-Response Characteristics of Various Peptides with Growth Hormone-Releasing Activity in the Unanesthetized Male Rat*

Publisher Website
Google Scholar
Abstract
The characterization of GH[growth hormone]-releasing peptides in vivo was complicated by the effects of endogenous hypothalamic regulation of GH secretion. A model to minimize endogenous hypothalamic interference by pretreating adult male rats with i.v. diethyldithiocarbamate and antisomatostatin serum is presented. This pretreatment regimen established stable, detectable basal levels of plasma GH and eliminated spontaneous GH pulses for 12 h. Repeated pulsatile administration of 400 ng/kg i.v. rat hypothalamic GH-releasing factor (rGRF) produced consistent GH responses. Linear, nearly identical, dose responses (from 300-5000 ng/kg) were observed with rGRF and human pancreatic GH-releasing factor (GRF44) with ED50 values of 1059.3 and 1116.9 ng/kg, respectively. A synthetic hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP), which was previously reported to have potent GH-releasing activity was also investigated. In contrast to either rGRF or GRF44, repeated administration of the same dose of GHRP did not produce consistent GH responses. The 1st bolus of GHRP produced a larger GH pulse than the second (P < 0.01), followed by increasing GH responses from injections 2-7. GHRP was about 2 log orders less potent than either rGRF or GRF44 on a molar basis. The disparity between the native peptides and GHRP suggests that the synthetic peptide may act to release GH through a different mechanism(s). Apparently, the diethyldithiocarbamate/anti-somatostatin serum-treated animal may be a useful model for investigating the pituitary actions of GH-releasing peptides.